Clinical Outcomes Associated with Anti-Xa-Guided Low-Molecular-Weight Heparin Therapy for Prophylaxis of Venous Thromboembolism
Poster-Audio {“type”:”audio”,”tracklist”:false,”tracknumbers”:true,”images”:false,”artists”:false,”tracks”:[{“src”:”https://2021.virtualpostercop.com/wp-content/uploads/2021/04/Poster-Audio.m4a”,”type”:”audio/mpeg”,”title”:””,”caption”:””,”description”:””,”meta”:{“length_formatted”:”1:39″},”image”:{“src”:”https://2021.virtualpostercop.com/wp-includes/images/media/audio.png”,”width”:48,”height”:64},”thumb”:{“src”:”https://2021.virtualpostercop.com/wp-includes/images/media/audio.png”,”width”:48,”height”:64}}]} Due to predictable pharmacokinetics and pharmacodynamics, patients receiving LMWH therapy do not require routine coagulation monitoring. Despite this, there is…
